Company Overview of AstraZeneca AB
AstraZeneca AB offers research, development, manufacture, and marketing of pharmaceutical products for gastrointestinal, cardiovascular, respiratory, and pain control.. The company was formerly known as Astra AB and changed its name to AstraZeneca AB in April 1999. The company was founded in 1913 and is based in Sodertalje, Sweden. AstraZeneca AB operates as a subsidiary of AstraZeneca PLC.
Sodertalje, 151 85
Founded in 1913
Key Executives for AstraZeneca AB
Compensation as of Fiscal Year 2015.
AstraZeneca AB Key Developments
AstraZeneca AB (publ) and Hutchison MediPharma Limited Announce Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer
Jun 1 15
AstraZeneca AB (publ) (AstraZeneca) and Hutchison MediPharma Limited's (HMP) collaboration partner, presented preliminary data from the ongoing Phase Ib clinical trial of HMP's c-Met inhibitor savolitinib (AZD6094) combined with AstraZeneca's drug candidate AZD9291 in non-small cell lung cancer ("NSCLC"). AZD9291 is AstraZeneca's investigational inhibitor of the epidermal growth factor receptor (EGFR). Preliminary data on the activity of AZD9291 in patients with EGFR mutation positive NSCLC who had failed currently-approved EGFR tyrosine kinase inhibitors was presented at the American Society of Clinical Oncology (ASCO) meeting in June 2014. In mid-2014 AstraZeneca commenced the TATTON study, a multi-arm Phase Ib study of AZD9291 in combination with either savolitinib (AZD6094) (c-MET inhibitor), MEDI4736 (anti-PD-L1 mAb) or selumetinib (MEK1/2 inhibitor) in EGFR mutation positive NSCLC. For those patients who received AZD9291 and savolitinib, the primary objective of the TATTON study was to establish a safe and effective combination dose. All patients were screened for their T790M status (+/-) as well as some, if sufficient tissue samples were available, for their c-Met (+/-) status. A total of 12 patients were dosed with either 600mg or 800mg daily doses of savolitinib (AZD6094) in combination with 80mg (once daily) AZD9291. In terms of the primary aims of the study, the 600mg combination dose was well tolerated with toxicity profiles that allow for combination at doses previously demonstrated to be biologically active. Of the 11 evaluable patients in the study, 6 partial responses (confirmed and unconfirmed) have been observed to date. Responses to date include 4 of 7 patients with confirmed T790M negative status.
AstraZeneca Plans To Invest In Biotech Drug Factory In Sodertalje
May 18 15
AstraZeneca AB is investing $285 million to expand biotech drug manufacturing in Sweden as the company bets on the future of high-tech medicine for future growth. The new facility for biological medicines in Sodertalje will supply medicines for clinical trial programs from the end of 2018 and will deliver finished products for commercial use once fully operational by 2019. The planned investment will, subject to relevant approvals by the local authorities, create between 150 and 250 highly skilled new roles at AstraZeneca by 2019, AstraZeneca said in a statement.
AstraZeneca AB Presents at Bio-Trinity, May-13-2015 10:10 AM
Apr 29 15
AstraZeneca AB Presents at Bio-Trinity, May-13-2015 10:10 AM. Venue: Novotel London West, 1 Shortlands, London W6 8DR, United Kingdom. Speakers: Christoph Pittius, VP, Head of Transactions, Business Development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|